Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 7, keine Gesamtzahl für „presented“
Suchtreffer
Begriffe & Kennungen
Gazyvaro · 4.8 · The incidences presented in the following sections if referring to iNHL are the highest incidence of that ADR
Eintrag öffnenGazyvaro · 4.8 · Undesirable effects are presented separately for the Oncology (Chronic lymphocytic leukaemia and Follicular ly
Eintrag öffnenGivlaari · 4.8 · The adverse reactions are presented as MedDRA preferred terms under the MedDRA system organ class (SOC) by fre
Eintrag öffnenGliolan · 4.8 · Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Eintrag öffnenGlivec · 4.8 · Within each frequency grouping, undesirable effects are presented in order of frequency, the most frequent fir
Eintrag öffnenGobivaz · 4.8 · Throughout this section, median duration of follow-up (approximately 4 years) is generally presented for all g
Eintrag öffnenGobivaz · 4.8 · Throughout this section, median duration of follow-up (approximately 4 years) is generally presented for all g
Eintrag öffnenGobivaz · 4.8 · Throughout this section, median duration of follow-up (approximately 4 years) is generally presented for all g
Eintrag öffnenGobivaz · 4.8 · Throughout this section, median duration of follow-up (approximately 4 years) is generally presented for all g
Eintrag öffnenGotenfia · 4.8 · Throughout this section, median duration of follow-up (approximately 4 years) is generally presented for all g
Eintrag öffnenGotenfia · 4.8 · Throughout this section, median duration of follow-up (approximately 4 years) is generally presented for all g
Eintrag öffnenHerceptin · 4.8 · Details of risk minimisation measures that are consistent with the EU Risk Management Plan are presented in (s
Eintrag öffnenHerceptin · 4.8 · Details of risk minimisation measures that are consistent with the EU Risk Management Plan are presented in Se
Eintrag öffnenHerceptin · 4.8 · Presented in Table 1 are adverse reactions that have been reported in association with the use of intravenous
Eintrag öffnenHerceptin · 4.8 · Presented in Table 1 are adverse reactions that have been reported in association with the use of intravenous
Eintrag öffnenHerwenda · 4.8 · Details of risk minimisation measures that are consistent with the EU Risk Management Plan are presented in se
Eintrag öffnenHerwenda · 4.8 · Presented in Table 1 are adverse reactions that have been reported in association with the use of intravenous
Eintrag öffnenHetronifly · 4.8 · * Adverse reaction frequencies presented in Table 2 may not be fully attributable to serplulimab alone but may
Eintrag öffnenHexyon · 4.8 · Within each frequency grouping the adverse reactions are presented in the order of decreasing seriousness.
Eintrag öffnenHumalog · 4.8 · Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Eintrag öffnen